The British-Swedish pharmaceutical company agreed on an initial batch of at least 400 million doses of the vaccine, with a total production capacity of one billion doses and with the first deliveries in September.
The United States has agreed to buy nearly a third of the first batch of a billion-dollar dose of AstraZeneca’s experimental vaccine for COVID-19 for up to $ 1.2 billion.
Although it remains to be seen whether it is effective, the vaccine seems to be the only way for many countries to restart their economies and secure a lead over other competitors.
The US Department of Health has agreed to allocate up to $ 1.2 billion to accelerate the development of a vaccine from AstraZeneca and to provide $ 300 million for the United States.
AstraZeneca today announced the signing of the first contracts for the supply of at least 400 million installments
vaccine, which he is developing in collaboration with the University of Oxford, and that he has the capacity to produce one million doses.
AstraZeneca has announced that clinical trials after the preliminary tests will involve 30,000 people.
as well as children, adding that the vaccine will be available in Britain in September.
AstraZeneca has acknowledged that the vaccine may not be effective, but if the test results are positive, it will lead to testing in several countries.
Only a small proportion of vaccines that are being developed have been tested in humans, which is an indicator of it
their safety and the stage at which most fail. At the moment, there are no approved treatments or vaccines for COVID-19 from any of the pharmaceutical giants that are testing them. Governments,
pharmaceutical and research centers are currently working on about 100 programs and experts
predict that it will take 12 to 18 months for an effective and safe vaccine to be available.
Other drugs that are in different stages of vaccine development are Pfizer, Johnson &
Johnson and Sanofi. And Moderna also announced positive results this week, as it reported that its vaccine had created antibodies in a small group of healthy volunteers.
naftemporiki.gr with information from Reuters, CNBC